

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Antisense-mediated splice intervention to treat... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-710/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-710" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Antisense-mediated splice intervention to treat human disease: the odyssey continues" />
    
            <meta name="og:title" content="F1000Research Article: Antisense-mediated splice intervention to treat human disease: the odyssey continues.">
            <meta name="og:description" content="Read the latest article version by Ianthe Pitout, Loren L. Flynn, Steve D. Wilton, Sue Fletcher, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="20203">
            <meta name="article-id" content="18466">
            <meta name="dc.title" content="Antisense-mediated splice intervention to treat human disease: the odyssey continues">
            <meta name="dc.description" content="Recent approvals of oligonucleotide analogue drugs to alter gene expression have been welcomed by patient communities but not universally supported. These compounds represent a class of drugs that are designed to target a specific gene transcript, and they include a number of chemical entities to evoke different antisense mechanisms, depending upon the disease aetiology.&amp;nbsp;To date, oligonucleotide therapeutics that are in the clinic or at advanced stages of translation target rare diseases, posing challenges to clinical trial design, recruitment and evaluation and requiring new evaluation paradigms. This review discusses the currently available and emerging therapeutics that alter exon selection through an effect on pre-mRNA splicing and explores emerging concerns over safety and efficacy. Although modification of synthetic nucleic acids destined for therapeutic application is common practice to protect against nuclease degradation and to influence drug function, such modifications may also confer unexpected physicochemical and biological properties. Negatively charged oligonucleotides have a strong propensity to bind extra- and intra-cellular proteins, whereas those analogues with a neutral backbone show inefficient cellular uptake but excellent safety profiles. In addition, the potential for incorporation of chemically modified nucleic acid monomers, yielded by nuclease degradation of exogenous oligonucleotides, into biomolecules has been raised and the possibility not entirely discounted. We conclude with a commentary on the ongoing efforts to develop novel antisense compounds and enhance oligonucleotide delivery in order to further improve efficacy and accelerate implementation of antisense therapeutics for human disease.">
            <meta name="dc.subject" content="antisense oligonucleotide, exon selection, alternative splicing">
            <meta name="dc.creator" content="Pitout, Ianthe">
            <meta name="dc.creator" content="Flynn, Loren L.">
            <meta name="dc.creator" content="Wilton, Steve D.">
            <meta name="dc.creator" content="Fletcher, Sue">
            <meta name="dc.date" content="2019/05/22">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.18466.1">
            <meta name="dc.source" content="F1000Research 2019 8:710">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="antisense oligonucleotide">
            <meta name="prism.keyword" content="exon selection">
            <meta name="prism.keyword" content="alternative splicing">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/05/22">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="710">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.18466.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-710">
            <meta name="citation_title" content="Antisense-mediated splice intervention to treat human disease: the odyssey continues">
            <meta name="citation_abstract" content="Recent approvals of oligonucleotide analogue drugs to alter gene expression have been welcomed by patient communities but not universally supported. These compounds represent a class of drugs that are designed to target a specific gene transcript, and they include a number of chemical entities to evoke different antisense mechanisms, depending upon the disease aetiology.&amp;nbsp;To date, oligonucleotide therapeutics that are in the clinic or at advanced stages of translation target rare diseases, posing challenges to clinical trial design, recruitment and evaluation and requiring new evaluation paradigms. This review discusses the currently available and emerging therapeutics that alter exon selection through an effect on pre-mRNA splicing and explores emerging concerns over safety and efficacy. Although modification of synthetic nucleic acids destined for therapeutic application is common practice to protect against nuclease degradation and to influence drug function, such modifications may also confer unexpected physicochemical and biological properties. Negatively charged oligonucleotides have a strong propensity to bind extra- and intra-cellular proteins, whereas those analogues with a neutral backbone show inefficient cellular uptake but excellent safety profiles. In addition, the potential for incorporation of chemically modified nucleic acid monomers, yielded by nuclease degradation of exogenous oligonucleotides, into biomolecules has been raised and the possibility not entirely discounted. We conclude with a commentary on the ongoing efforts to develop novel antisense compounds and enhance oligonucleotide delivery in order to further improve efficacy and accelerate implementation of antisense therapeutics for human disease.">
            <meta name="citation_description" content="Recent approvals of oligonucleotide analogue drugs to alter gene expression have been welcomed by patient communities but not universally supported. These compounds represent a class of drugs that are designed to target a specific gene transcript, and they include a number of chemical entities to evoke different antisense mechanisms, depending upon the disease aetiology.&amp;nbsp;To date, oligonucleotide therapeutics that are in the clinic or at advanced stages of translation target rare diseases, posing challenges to clinical trial design, recruitment and evaluation and requiring new evaluation paradigms. This review discusses the currently available and emerging therapeutics that alter exon selection through an effect on pre-mRNA splicing and explores emerging concerns over safety and efficacy. Although modification of synthetic nucleic acids destined for therapeutic application is common practice to protect against nuclease degradation and to influence drug function, such modifications may also confer unexpected physicochemical and biological properties. Negatively charged oligonucleotides have a strong propensity to bind extra- and intra-cellular proteins, whereas those analogues with a neutral backbone show inefficient cellular uptake but excellent safety profiles. In addition, the potential for incorporation of chemically modified nucleic acid monomers, yielded by nuclease degradation of exogenous oligonucleotides, into biomolecules has been raised and the possibility not entirely discounted. We conclude with a commentary on the ongoing efforts to develop novel antisense compounds and enhance oligonucleotide delivery in order to further improve efficacy and accelerate implementation of antisense therapeutics for human disease.">
            <meta name="citation_keywords" content="antisense oligonucleotide, exon selection, alternative splicing">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Ianthe Pitout">
            <meta name="citation_author_institution" content="Murdoch University, Murdoch, WA, 6150, Australia">
            <meta name="citation_author" content="Loren L. Flynn">
            <meta name="citation_author_institution" content="Murdoch University, Murdoch, WA, 6150, Australia">
            <meta name="citation_author_institution" content="The University of Western Australia, Nedlands, WA, 6009, Australia">
            <meta name="citation_author_institution" content="Perron Institute, Nedlands, WA, 6009, Australia">
            <meta name="citation_author" content="Steve D. Wilton">
            <meta name="citation_author_institution" content="Murdoch University, Murdoch, WA, 6150, Australia">
            <meta name="citation_author_institution" content="The University of Western Australia, Nedlands, WA, 6009, Australia">
            <meta name="citation_author_institution" content="Perron Institute, Nedlands, WA, 6009, Australia">
            <meta name="citation_author" content="Sue Fletcher">
            <meta name="citation_author_institution" content="Murdoch University, Murdoch, WA, 6150, Australia">
            <meta name="citation_author_institution" content="The University of Western Australia, Nedlands, WA, 6009, Australia">
            <meta name="citation_author_institution" content="Perron Institute, Nedlands, WA, 6009, Australia">
            <meta name="citation_publication_date" content="2019/05/22">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="710">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.18466.1">
            <meta name="citation_firstpage" content="710">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-710/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-710.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=20203 /> <input type=hidden id=articleId name=articleId value=18466 /> <input type=hidden id=xmlUrl value="/articles/8-710/v1/xml"/> <input type=hidden id=xmlFileName value="-8-710-v1.xml"> <input type=hidden id=article_uuid value=78a31033-6e85-4dad-a79f-5178f8be5643 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Antisense-mediated splice intervention to treat human disease: the odyssey continues"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.18466.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.18466.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-710"
  },
  "headline": "Antisense-mediated splice intervention to treat human disease: the odyssey continues",
  "datePublished": "2019-05-22T16:11:46",
  "dateModified": "2019-05-22T16:11:46",
  "author": [
    {
      "@type": "Person",
      "name": "Ianthe Pitout"
    },    {
      "@type": "Person",
      "name": "Loren L. Flynn"
    },    {
      "@type": "Person",
      "name": "Steve D. Wilton"
    },    {
      "@type": "Person",
      "name": "Sue Fletcher"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Recent approvals of oligonucleotide analogue drugs to alter gene expression have been welcomed by patient communities but not universally supported. These compounds represent a class of drugs that are designed to target a specific gene transcript, and they include a number of chemical entities to evoke different antisense mechanisms, depending upon the disease aetiology. To date, oligonucleotide therapeutics that are in the clinic or at advanced stages of translation target rare diseases, posing challenges to clinical trial design, recruitment and evaluation and requiring new evaluation paradigms. This review discusses the currently available and emerging therapeutics that alter exon selection through an effect on pre-mRNA splicing and explores emerging concerns over safety and efficacy. Although modification of synthetic nucleic acids destined for therapeutic application is common practice to protect against nuclease degradation and to influence drug function, such modifications may also confer unexpected physicochemical and biological properties. Negatively charged oligonucleotides have a strong propensity to bind extra- and intra-cellular proteins, whereas those analogues with a neutral backbone show inefficient cellular uptake but excellent safety profiles. In addition, the potential for incorporation of chemically modified nucleic acid monomers, yielded by nuclease degradation of exogenous oligonucleotides, into biomolecules has been raised and the possibility not entirely discounted. We conclude with a commentary on the ongoing efforts to develop novel antisense compounds and enhance oligonucleotide delivery in order to further improve efficacy and accelerate implementation of antisense therapeutics for human disease."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-710.html",
            "name": "Antisense-mediated splice intervention to treat human disease: the..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Antisense-mediated splice intervention to treat human disease: the... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=20203 data-id=18466 data-downloads="" data-views="" data-scholar="10.12688/f1000research.18466.1" data-recommended="" data-doi="10.12688/f1000research.18466.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-710/v1/pdf?article_uuid=78a31033-6e85-4dad-a79f-5178f8be5643" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-18466-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-18466-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-18466-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Pitout I, Flynn LL, Wilton SD and Fletcher S. Antisense-mediated splice intervention to treat human disease: the odyssey continues [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):710 (<a class=new-orange href="https://doi.org/10.12688/f1000research.18466.1" target=_blank>https://doi.org/10.12688/f1000research.18466.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-18466-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=18466 id=track-article-signin-18466 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/18466?target=/articles/8-710.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=20203 /> <input name=articleId type=hidden value=18466 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Antisense-mediated splice intervention to treat human disease: the odyssey continues</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Ianthe Pitout<sup>1</sup>,&nbsp;</span><span class="">Loren L. Flynn<sup>1-3</sup>,&nbsp;</span><span class="">Steve D. Wilton<sup>1-3</sup>,&nbsp;</span><span class=""><a href="mailto:sfletcher@ccg.murdoch.edu.au" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Sue Fletcher</span></a><a href="https://orcid.org/0000-0002-8632-641X" target=_blank id=author-orcid-3><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-3><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-8632-641X</div><sup>1-3</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Ianthe Pitout<sup>1</sup>,&nbsp;</span><span class="">Loren L. Flynn<sup>1-3</sup>,&nbsp;</span><span class="">Steve D. Wilton<sup>1-3</sup>,&nbsp;</span><span class=""><a href="mailto:sfletcher@ccg.murdoch.edu.au" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Sue Fletcher</span></a><a href="http://orcid.org/0000-0002-8632-641X" target=_blank id=mauthor-orcid-3><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-3><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-8632-641X</div><sup>1-3</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 22 May 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.18466.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Murdoch University, Murdoch, WA, 6150, Australia<br/> <sup>2</sup> The University of Western Australia, Nedlands, WA, 6009, Australia<br/> <sup>3</sup> Perron Institute, Nedlands, WA, 6009, Australia<br/> <p> <div class=margin-bottom> Ianthe Pitout <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Loren L. Flynn <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Steve D. Wilton <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Sue Fletcher <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=51010-48520></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=51011-48521></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=51012-48519></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Recent approvals of oligonucleotide analogue drugs to alter gene expression have been welcomed by patient communities but not universally supported. These compounds represent a class of drugs that are designed to target a specific gene transcript, and they include a number of chemical entities to evoke different antisense mechanisms, depending upon the disease aetiology.&nbsp;To date, oligonucleotide therapeutics that are in the clinic or at advanced stages of translation target rare diseases, posing challenges to clinical trial design, recruitment and evaluation and requiring new evaluation paradigms. This review discusses the currently available and emerging therapeutics that alter exon selection through an effect on pre-mRNA splicing and explores emerging concerns over safety and efficacy. Although modification of synthetic nucleic acids destined for therapeutic application is common practice to protect against nuclease degradation and to influence drug function, such modifications may also confer unexpected physicochemical and biological properties. Negatively charged oligonucleotides have a strong propensity to bind extra- and intra-cellular proteins, whereas those analogues with a neutral backbone show inefficient cellular uptake but excellent safety profiles. In addition, the potential for incorporation of chemically modified nucleic acid monomers, yielded by nuclease degradation of exogenous oligonucleotides, into biomolecules has been raised and the possibility not entirely discounted. We conclude with a commentary on the ongoing efforts to develop novel antisense compounds and enhance oligonucleotide delivery in order to further improve efficacy and accelerate implementation of antisense therapeutics for human disease. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> antisense oligonucleotide, exon selection, alternative splicing </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Sue Fletcher (<a href="mailto:sfletcher@ccg.murdoch.edu.au">sfletcher@ccg.murdoch.edu.au</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Sue Fletcher </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> SF and SDW serve as consultants to Sarepta Therapeutics and are named on intellectual property licensed to Sarepta Therapeutics by the University of Western Australia. The other authors declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2019 Pitout I <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Pitout I, Flynn LL, Wilton SD and Fletcher S. Antisense-mediated splice intervention to treat human disease: the odyssey continues [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):710 (<a href="https://doi.org/10.12688/f1000research.18466.1" target=_blank>https://doi.org/10.12688/f1000research.18466.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 22 May 2019, <b>8</b>(F1000 Faculty Rev):710 (<a href="https://doi.org/10.12688/f1000research.18466.1" target=_blank>https://doi.org/10.12688/f1000research.18466.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 22 May 2019, <b>8</b>(F1000 Faculty Rev):710 (<a href="https://doi.org/10.12688/f1000research.18466.1" target=_blank>https://doi.org/10.12688/f1000research.18466.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d18937e210>Introduction</h2><p class="" id=d18937e213>The integrity of all gene expression is reliant on RNA, and the property of nucleic acids that permits complementary base pairing has long been an attractive option to alter gene expression by modulating RNA structure, function or abundance to treat human disease. Advances in the field have been predicated upon development of synthetic nucleic acid analogues (for review, see <a href="#ref-1">1</a>) that resist nuclease degradation and can be modified to evoke specific mechanisms. An antisense (the reverse complement) nucleic acid sequence (oligonucleotide) to a region of the target molecule can be designed and evaluated in a routine manner to identify compounds with the required specificity and affinity to alter the abundance, structure or functionality of the resulting transcript (<a href="#f1">Figure 1</a>). Such outcomes have far-reaching potential to alter the course of human diseases, and at this time, the indications are mostly rare inherited conditions with otherwise limited treatment options. The field has attracted some debate regarding the high treatment costs, clinical trial and regulatory evaluation outcomes and approvals, some uncertainty regarding mechanisms of action<sup><a href="#ref-1">1</a></sup> and emerging reports of off-target effects<sup><a href="#ref-2">2</a>,<a href="#ref-3">3</a></sup>. Although only a small number of antisense drugs are in the clinic<sup><a href="#ref-4">4</a></sup> or undergoing translation at this time, ongoing efforts to improve oligonucleotide drug delivery and efficacy and to better understand antisense mechanisms will drive further advances in the field.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/20203/c59f19fd-faa5-444b-b15a-9372a2479a33_figure1.gif"><img alt="c59f19fd-faa5-444b-b15a-9372a2479a33_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/20203/c59f19fd-faa5-444b-b15a-9372a2479a33_figure1.gif"></a><div class=caption><h3>Figure 1. Currently approved antisense oligonucleotide drugs, indicating chemistry and mechanisms of action.</h3><p id=d18937e247>Antisense strategies that induce transcript degradation (left panel) include RNaseH degradation of the target transcript, activated by annealing of a complementary oligodeoxynucleotide (<b>A</b>) and transcript degradation by small interfering RNA (siRNA) (<b>B</b>). Transcript modification by RNA analogues (right panel) can be achieved by targeting splice motifs to exclude an exon to alter the reading frame or remove exons carrying mutations (<b>C</b>) or strengthen exon selection, otherwise compromised by base changes (<b>D</b>). 2′-O-MOE, 2′-<i>O</i>-(2-methoxyethyl); <i>DMD</i>, dystrophin; <i>ISS-N1</i>, intron splice silencer N1; PMO, phosphorodiamidate morpholino oligomer; PO, phosphodiester; PS, phosphorothioate; RISC, RNA-induced silencing complex; <i>SMN2</i>, survival motor neuron 2.</p></div></div><p class="" id=d18937e279>Natural nucleic acids are biologically labile and their application in drug development has required chemical modifications of the bases and nucleic acid backbone to increase resistance to endogenous nucleases and influence activity. The phosphorothioate backbone is the most widely applied chemical modification (<a href="#f2">Figure 2</a>), and although the substitution of sulphur for a non-bridging oxygen confers nuclease stability, changes to the ribose moiety can confer RNA-like characteristics and hydrophobicity to the oligonucleotide (for example, 2′-<i>O</i>-methyl, 2′-<i>O</i>-methoxyethyl and 2′-<i>O</i>-fluoro). Phosphorothioate oligonucleotides carry a strong negative charge, allowing binding to various proteins and complex formation with cationic liposomes for efficient transfection <i>in vitro.</i> Other nucleobase and backbone modifications can confer specific characteristics and mechanisms of action, and include peptide nucleic acids and phosphorodiamidate morpholino oligomers (PMOs) (<a href="#f2">Figure 2</a>) that carry a neutral charge but show inefficient cellular uptake (for review, see <a href="#ref-5">5</a>).</p><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/20203/c59f19fd-faa5-444b-b15a-9372a2479a33_figure2.gif"><img alt="c59f19fd-faa5-444b-b15a-9372a2479a33_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/20203/c59f19fd-faa5-444b-b15a-9372a2479a33_figure2.gif"></a><div class=caption><h3>Figure 2. Natural and chemically modified nucleotides.</h3><p id=d18937e314>Upper panel: DNA, RNA and phosphorothioate (sulphur substituted for a non-bridging oxygen)-modified nucleotide (PS DNA). Lower panel: 2′-<i>O</i>-methyl phosphorothioate (2′-OMePS), 2′-<i>O</i>-methoxyethyl phosphorothioate (2′-O-MOE-PS) and phosphorodiamidate morpholino oligomer (PMO).</p></div></div><p class="" id=d18937e328>The more widely exploited antisense strategies use DNA analogues that activate RNase H1 degradation of the target transcript (<a href="#f1">Figure 1</a>), and thereby downregulate gene expression, or double-stranded RNAs to induce gene silencing, comprehensively reviewed by Shen and Corey<sup><a href="#ref-6">6</a></sup>. The concept of altering splice site selection to modify disease-causing transcripts was validated <i>in vitro</i> over 25 years ago<sup><a href="#ref-7">7</a></sup> and requires the design and application of an RNA analogue that targets motifs participating in exon selection and retention in the mature mRNA. Antisense targeting of splice sites or motifs necessary for exon selection can influence endogenous alternative splicing, block aberrant splicing, exclude a cryptic exon or an exon carrying a disease-causing mutation, or restore the open reading frame around a frame-shifting deletion, whereas targeting splicing silencers can enhance selection of an exon, otherwise compromised by nucleotide changes (for reviews, see <a href="#ref-8">8</a>,<a href="#ref-9">9</a>).</p><p class="" id=d18937e352>At this time, two mRNA splice-modulating drugs are reported to have delivered therapeutic benefit to a subset of patients with Duchenne muscular dystrophy (DMD)<sup><a href="#ref-10">10</a></sup> and to patients with spinal muscular atrophy (SMA)<sup><a href="#ref-11">11</a></sup>. <i>Eteplirsen</i> (<i>Exondys51)</i>, Sarepta Therapeutics, Cambridge, MA, USA) is an antisense PMO that targets splice enhancer motifs in the <i>DMD</i> pre-mRNA to exclude exon 51 and restore the dystrophin mRNA reading frame, disrupted by most deletions beginning at exon 52 or ending at exon 50. <i>Eteplirsen</i> received accelerated approval from the US Food and Drug Administration (FDA) in September 2016 but is not yet approved in Europe. The drug <i>nusinersen</i> (<i>Spinraza</i> <sup>®</sup>, Biogen, Cambridge, MA, USA) for the treatment of SMA is a 2′-<i>O</i>-methoxyethyl antisense oligonucleotide (AO) on a phosphorothioate backbone. <i>Nusinersen</i> targets a splice silencer (<i>ISS-N1</i>) in survival motor neuron 2 (<i>SMN2</i>) intron 7 and promotes exon 7 selection and retention during pre-mRNA splicing<sup><a href="#ref-12">12</a></sup> and was approved by the FDA in December 2016. The roughly 25-year history of antisense drug development parallels that of an increasing interest in therapeutics for rare diseases. Of patients with any of the more than 6,000 rare diseases described to date, only a few groups of patients benefit from an effective treatment. It is perhaps fitting that the first splice intervention antisense therapeutics to reach the clinic address two of the more common and debilitating of the life-limiting inherited rare diseases of childhood. This review focuses on the development and current status of AO drugs that alter exon selection and exert a therapeutic effect by restoring or altering protein structure and function.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d18937e405>RNA splice-modulating drugs in the clinic</h2><p class="" id=d18937e408>The field of RNA splicing therapeutics was launched by the demonstration of AO-mediated suppression of a disease-causing cryptic splice site in the β-globin transcript in a cell-free system<sup><a href="#ref-7">7</a></sup>. This was followed by parallel programs to develop RNA therapeutics to alter exon selection during processing of the dystrophin (<i>DMD</i>) pre-mRNA and generate internally truncated but functional dystrophin isoforms that reflect variants found in the less severe allelic disorder, Becker muscular dystrophy (for review, see <a href="#ref-13">13</a>). Over 60% of the DMD-causing mutations are deletions of one or more exons, predominantly between exons 43 and 53 (major deletion hotspot) or exons 3 and 7 (minor deletion hotspot), that disrupt the translational reading frame and yield a prematurely truncated, non-functional protein. Becker muscular dystrophy is less common and is the consequence of mutations that yield a protein of reduced function or abundance or both. Becker muscular dystrophy mutations are generally in-frame deletions and provide “templates” for partially functional dystrophin variants that could ameliorate the severe dystrophic muscle phenotype characteristic of DMD. While the dystrophin exon-skipping programs aimed to develop antisense oligomer sequences that prevent exon selection during dystrophin pre-mRNA splicing (exon skipping) to generate internally truncated dystrophin molecules, two different RNA-like analogue chemistries were used for translational development. </p><div class=section><a name=d18937e421 class=n-a></a><h3 class=section-title>Antisense treatment to restore dystrophin expression</h3><p class="" id=d18937e426>Two experimental antisense drugs, both designed to treat DMD in a subset of patients by removing dystrophin exon 51 and re-frame the transcript around disease-causing deletions that flank exon 51, such as exon 50, exons 48 to 50 or exon 52, were evaluated in independent clinical trials and presented for regulatory consideration in 2015. The investigational drug <i>drisapersen</i>, a 2′-<i>O</i>-methyl–modified AO on a phosphorothioate backbone, was evaluated in 186 ambulant participants with DMD by using subcutaneous injections at a dosage of 6 mg/kg per week in an extended study over the course of 188 weeks<sup><a href="#ref-14">14</a></sup>. Although the drug was reported to be generally well tolerated<sup><a href="#ref-14">14</a></sup>, renal effects, thrombocytopenia and injection site reactions have attracted attention<sup><a href="#ref-15">15</a></sup>. <i>Drisapersen</i> failed to meet primary and secondary endpoints and, in light of the considerable adverse side effects, was withdrawn from further development after negative feedback from the regulators. (For comprehensive review of antisense therapeutics for neuromuscular disease, see <a href="#ref-16">16</a>.) Injection site reactions and skin abnormalities as a consequence of long-term subcutaneous <i>drisapersen</i> injection remain unresolved even long after cessation of treatment<sup><a href="#ref-15">15</a>,<a href="#ref-17">17</a></sup>.</p><p class="" id=d18937e464> <i>Eteplirsen</i> is a PMO delivered by once-weekly intravenous infusion (30 mg/kg) that also targets dystrophin exon 51 and received accelerated approval from the FDA in 2016. The approval of <i>eteplirsen</i> evoked lively discussion<sup><a href="#ref-18">18</a>–<a href="#ref-21">21</a></sup> largely because of the small study group; use of a trial structure that had the placebo cohort transition to treatment after 6 months, when the difference in ambulation, the primary endpoint, reached significance; and the low (relative to healthy) levels of muscle dystrophin induced by the treatment<sup><a href="#ref-10">10</a></sup>. In the aftermath of FDA review and concern regarding the efficacy of <i>eteplirsen</i>, much attention focused on dystrophin quantitation and clinical trial outcome measures. However, seven years after initiation of Sarepta Therapeutics study 201 and completion of the extension study 202 (long-term safety and efficacy), the trial participants receiving <i>eteplirsen</i> continue to show functional benefits, respiratory function decline is half that expected from the natural history of the disease<sup><a href="#ref-22">22</a></sup>, and no treatment-related serious adverse events have been reported. Class II evidence of increased dystrophin expression over baseline dystrophin was presented<sup><a href="#ref-23">23</a></sup>, and although the treatment regimen is costly (more than $300,000 per year for a 25-kg child; for review, see <a href="#ref-24">24</a>) and the weekly intravenous treatment regimen can be burdensome for patients and their families, continued ambulation in teenage patients with DMD<sup><a href="#ref-10">10</a></sup>, together with respiratory benefits<sup><a href="#ref-22">22</a></sup>, represents a marked deviation from the natural history of the disease, is unprecedented and sets a benchmark for future dystrophin-restoring therapies.</p></div><div class=section><a name=d18937e511 class=n-a></a><h3 class=section-title>Spinal muscular atrophy</h3><p class="" id=d18937e516>SMA is a recessive disease characterized by deficiency of SMN protein that leads to the selective loss of spinal motor neurons and skeletal muscle paralysis, affecting the trunk and limbs. SMA is the most common genetic cause of infant mortality with a prevalence of 1 in about 11,000 live births and carrier frequency of 1 in 40 to 67, depending on ethnicity<sup><a href="#ref-25">25</a></sup>. The genetic defect in 95% of cases is homozygous deletion of the <i>SMN1</i> gene and while the <i>SMN2</i> gene, present in all patients with SMA, potentially encodes an identical protein, a synonymous C&gt;T variant in exon 7 leads to aberrant processing of the mRNA. <i>SMN2</i> copy number is polymorphic, and there is some inverse correlation between the number of copies of <i>SMN2</i> and disease severity. An AO targeting an intronic splice silencer motif, <i>ISS-N1</i><sup><a href="#ref-12">12</a></sup>, increased full-length <i>SMN</i> transcript in pre-clinical studies, and the 2′-<i>O</i>-methoxyethyl phosphorothioate AO was approved under the name <i>spinraza</i> after a randomized placebo-controlled clinical trial<i>.</i> The patients who received intrathecal injection of <i>nusinersen</i> (12 mg) showed increased event-free survival and significant improvements in motor function, not seen in patients with SMA type 1<sup><a href="#ref-11">11</a></sup>, prompting early termination of the study<sup><a href="#ref-26">26</a></sup>. Comprehensive review and analysis of <i>nusinersen</i> treatment in SMA by the Canadian Agency for Drugs and Technologies in Health include commentary on the cost-benefit (at a cost of $708,000 in year 1 for four treatments of 12 mg and $354,000 annually for maintenance treatments thereafter)<sup><a href="#ref-27">27</a></sup>. <i>Nusinersen</i> is now available in many European countries, the USA, Canada, Australia, New Zealand and Japan and is reported to deliver clinical benefit in both SMA type 1 and type 2 patients<sup><a href="#ref-28">28</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d18937e585>Splice-modifying therapies under development</h2><p class="" id=d18937e588>Pre-clinical and clinical studies on novel splice-modulating experimental drugs are gaining momentum. (For review of splice-modifying oligonucleotides under development, see <a href="#ref-9">9</a>.) Current strategies include dystrophin exon-skipping programs, exons 45 <i>casimersen</i> (SRP-4045) and 53 <i>golodirsen</i> (SRP-4053) by Sarepta Therapeutics (<a target=xrefwindow href="https://www.sarepta.com/pipeline/exon-skipping-duchenne" id=d18937e599>https://www.sarepta.com/pipeline/exon-skipping-duchenne</a>); an unrelated dystrophin exon 53 program<sup><a href="#ref-29">29</a>,<a href="#ref-30">30</a></sup>; exon-skipping strategies to treat dysferlinopathies (for example, limb girdle muscular dystrophy type 2B) by excluding exons 37 and 38 in a <i>Dysf</i> mutant mouse model; targeting cryptic exons activated by deep intronic mutations causing choroideremia<sup><a href="#ref-31">31</a></sup>, Leber congenital amaurosis<sup><a href="#ref-32">32</a></sup> and USH2A-associated retinal degeneration<sup><a href="#ref-33">33</a></sup>; correction of mis-splicing of harmonium in USH1C and exon inclusion to address a common splice variant causing adult-onset Pompe disease<sup><a href="#ref-34">34</a></sup>. Two different exon-skipping strategies to treat spinocerebellar ataxia type 3 were recently reported. The pathogenic expanded polyglutamine repeat can be removed by skipping exon 10<sup><a href="#ref-35">35</a></sup>; however, in an innovative strategy, exons 8 and 9 were skipped in order to prevent proteolytic cleavage and generation of toxic protein fragments<sup><a href="#ref-36">36</a></sup>.</p><p class="" id=d18937e639>Though not widely exploited, modulation of endogenous alternative splicing to alter isoform ratios could have broad applicability to a number of acquired and inherited phenotypes. AO-mediated switching of <i>Bcl-x</i> splicing from the anti-apoptotic isoform to the pro-apoptotic isoform induced apoptosis of glioma cell lines<sup><a href="#ref-37">37</a></sup> and of hepatic stellate cells in liver fibrosis studies<sup><a href="#ref-38">38</a></sup>. Endogenous aberrant splicing of <i>GNB3</i> was corrected by AO-mediated splice intervention<sup><a href="#ref-39">39</a></sup>. The <i>LMNA</i> gene encodes two alternatively spliced products that are major components of the nuclear envelope. Mutations in the pre-lamin A transcript can result in aberrant splicing, causing Hutchison–Gilford progeria syndrome that can be addressed either by AO targeting of the cryptic splice site (for review, see <a href="#ref-40">40</a>) or by manipulating splicing of exon 11 to favour the lamin C isoform<sup><a href="#ref-41">41</a></sup>.</p><p class="" id=d18937e671>Although development of novel molecular therapeutics is eagerly anticipated by patients and families and has instigated efforts to find new targets and intervention opportunities, current limitations to broader applicability need to be overcome, primarily inefficient delivery to target tissues. The charge-neutral PMOs have an excellent safety profile but are rapidly cleared from the circulation, showing poor uptake into cells. Pre-clinical development of exon-skipping PMOs in a mouse muscular dystrophy model showed moderate restoration of skeletal muscle dystrophin but minimal uptake in the myocardium<sup><a href="#ref-42">42</a></sup>. Systemic delivery of these molecules can be greatly improved by conjugation to cell-penetrating peptides<sup><a href="#ref-43">43</a>,<a href="#ref-44">44</a></sup>, the use of novel strategies, such as exploiting exosomes and targeting peptides<sup><a href="#ref-45">45</a></sup>, and gaining greater insights into the mechanisms of cell uptake<sup><a href="#ref-46">46</a></sup>. Successful translation of peptide-phosphorodiamidate morpholino drugs that are currently in development and clinical evaluation (for example, for DMD) may well begin a new era for splice-modifying therapies, particularly if tissue or cell targeting can be achieved, perhaps leading to reduced dosages.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d18937e696>Non-antisense and off-target effects of synthetic oligonucleotides</h2><p class="" id=d18937e699>Oligonucleotide backbone and sugar modifications influence resistance to nucleases, mechanism of action, tissue distribution and binding to various proteins but can also cause hybridization-dependent (off-target hybridization of RNase H1-competent AOs resulting in hepatotoxicity<sup><a href="#ref-47">47</a></sup>) and independent effects. Phosphorothioate oligonucleotides administered <i>in vivo</i> bind to serum and cellular proteins<sup><a href="#ref-2">2</a>,<a href="#ref-48">48</a></sup> (for review, see <a href="#ref-49">49</a>) and show good tissue uptake and distribution, in the brain in particular<sup><a href="#ref-50">50</a></sup>. However, in a systematic literature review of original trial reports, by van Meer <i>et al</i>.<sup><a href="#ref-51">51</a></sup>, all studies involving phosphorothioate oligonucleotides administered subcutaneously report injection site reactions, while intravenous delivery was associated with thrombocytopenia. Phosphorothioate oligonucleotide sequences were reported to be immunostimulatory<sup><a href="#ref-52">52</a></sup> and to bind to platelets, eliciting strong platelet-activating effects<sup><a href="#ref-53">53</a></sup>, while intracerebroventricular injection of 2′-<i>O</i>-methyl phosphorothioate AOs upregulated immune system-associated genes<sup><a href="#ref-50">50</a></sup>. More recently, antisense drugs include modifications to enhance affinity (for example, locked nucleic acids or constrained ethyl substituted gapmers) that are reported to cause hepatotoxicity due to off-target RNA hybridization and downregulation<sup><a href="#ref-47">47</a>,<a href="#ref-54">54</a></sup>. In an elegant study, Dieckmann <i>et al</i>.<sup><a href="#ref-54">54</a></sup> showed that hybridization-dependent toxicity of RNase H1-competent phosphorothioate oligonucleotides can be mitigated by limiting the affinity of the oligonucleotide and improving target specificity.</p><p class="" id=d18937e761>The propensity for phosphorothioate oligonucleotides to cause injection site reactions<sup><a href="#ref-15">15</a>,<a href="#ref-17">17</a></sup>, flu-like symptoms, and hepatotoxicity was well known prior to the <i>drisapersen</i> exon-skipping studies and was reported in patients who received the approved drug <i>mipomersen</i> (RNase H1-competent gapmer) for the treatment of homozygous hypercholesteremia<sup><a href="#ref-55">55</a>,<a href="#ref-56">56</a></sup>.</p><p class="" id=d18937e784>Although the hepatotoxicity may be attributable in part to off-target hybridization, the exact cause of the injection site reactions remains unknown. Shen <i>et al</i>.<sup><a href="#ref-57">57</a></sup> examined cells transfected with phosphorothioate oligonucleotides with various 2′ modifications. They found that these compounds bind a large number of intracellular proteins and can replace the architectural long non-coding RNA <i>NEAT1</i> in subnuclear bodies called paraspeckles. The repertoire of proteins bound by phosphorothioate AOs and the effects of protein depletion or altered cellular localization are influenced by any 2′ modification<sup><a href="#ref-58">58</a></sup>. The most widely used modification, 2′-<i>O</i>-methoxyethyl, was found to have an acceptable tolerability profile and consistent behaviour between sequences<sup><a href="#ref-3">3</a></sup>, whereas 2′-fluoro-modified phosphorothioate oligonucleotides disturb nuclear biology, impair cell proliferation and cause loss of cellular proteins<sup><a href="#ref-59">59</a></sup>.</p><p class="" id=d18937e813>We explored the interaction of 2′-<i>O</i>-methyl phosphorothioate AOs with nuclear proteins and report backbone-specific effects of modified oligonucleotides on subnuclear organelles, altered distribution of nuclear proteins, the appearance of novel large structured nuclear inclusions, modification of RNA processing and marked disturbance of the transcriptome in cultured cells. We speculate that some side effects and adverse events reported after clinical evaluation of phosphorothioate nucleic acid drugs may be mediated, at least in part, by non-specific interaction of nuclear components with the phosphorothioate backbone<sup><a href="#ref-60">60</a></sup>. The sequence-independent effects of phosphorothioate compounds indeed may enhance or confound apparent antisense effects<sup><a href="#ref-61">61</a></sup> as a consequence of extensive disturbance of nuclear proteins and organelles, particularly those critical for RNA processing and splicing. Strategies to reduce cellular protein binding by phosphorothioate AOs and mitigate toxic effects, thereby improving the therapeutic profile of these molecules by backbone<sup><a href="#ref-62">62</a></sup> and 2′-<i>O</i>-modifications<sup><a href="#ref-63">63</a></sup> are important steps in guiding AO design. Other considerations that may warrant comprehensive investigation are whether phosphorothioate nucleotide degradation products are incorporated into cellular nucleic acids, a question that has been raised<sup><a href="#ref-64">64</a></sup>, and whether the immune activation by intra-cerebroventricular injection of a 2′-<i>O</i>-methyl phosphorothioate AO reported in mice<sup><a href="#ref-50">50</a></sup> should be of concern in humans who receive similar compounds.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d18937e853>Molecular medicines in the future</h2><p class="" id=d18937e856>In an era of promising gene replacement and gene correction strategies, exploiting novel recombinant viruses that can be selected and tailored for tropism to specific tissues, the rationale for pursuing transcript-modifying therapies might be questioned. Many of these emerging molecular and gene therapeutics target rare and life-limiting diseases caused by multiple gene variants that may show variable progression and phenotypes within one patient group and, in the event that more than one treatment modality is investigated, compete for the same restricted patient population in recruiting clinical trial participants.</p><p class="" id=d18937e859>However, consider the situation where different treatment modalities could be used in tandem. For example, an antisense strategy might be the only option following vector gene delivery if the virus results in seroconversion and precludes re-delivery. PMOs designed to alter exon selection are specific to the target transcript and, to the best of our knowledge, have not been reported to cause off-target effects on splicing and have no effect when delivered to cells lacking the target transcript. In the case of cryptic exon or aberrant splice site usage, antisense-mediated strategies can generate a normal product, unlikely to be immunogenic, that is expressed under endogenous, tissue/cell/developmental regulation. Gain-of-function mutations may be particularly amenable to splice interventions, whereas for loss-of-function mutations, splice variants can be designed to encode products that may exhibit reduced function but could ameliorate otherwise severe disease.</p><p class="" id=d18937e862>We conclude by acknowledging the contribution of the patients and the combined efforts of chemists, researchers and clinicians and those in the biopharmaceutical industry who championed these drugs and the insightful regulators who have yielded two splice interventions, now available to patients. Although there is general agreement that better drug uptake and greater efficacy are desirable, these drugs, by all accounts, are altering the course of previously untreatable disease. There is potential for numerous therapeutics in the “splice modulating” class. The lessons learnt over the course of translating <i>eteplirsen</i> and <i>nusinersen</i> and from the failure of <i>drispersen</i> will inform the development of emerging and future molecular medicines.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d18937e878>Abbreviations</h2><p class="" id=d18937e881>AO, antisense oligonucleotide; DMD, Duchenne muscular dystrophy; FDA, US Food and Drug Administration; PMO, phosphorodiamidate morpholino oligomer; SMA, spinal muscular atrophy; SMN, survival motor neuron</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d18937e1 class=n-a></a><h2 class=main-title id=d19122>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d18937e888 class=n-a></a><h2 class=main-title id=d18937e890>Acknowledgements</h2><p class="" id=d18937e893>The authors are grateful to Rakesh N. Veedu, Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University for the preparation of <a href="#f2">Figure 2</a>.</p></div><div class=back-section><a name=d18937e900 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d19347>References</h2><div class="section ref-list"><a name=d18937e900 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d18937e907 class=n-a></a>Dias N, Stein CA: Antisense oligonucleotides: basic concepts and mechanisms. <i>Mol Cancer Ther.</i> 2002; <b>1</b>(5): 347–55. <a target=xrefwindow id=d18937e915 href="http://www.ncbi.nlm.nih.gov/pubmed/12489851">PubMed Abstract </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d18937e924 class=n-a></a>Liang XH, Sun H, Shen W, <i> et al.</i>: Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages. <i>Nucleic Acids Res.</i> 2015; <b>43</b>(5): 2927–45. <a target=xrefwindow id=d18937e935 href="http://www.ncbi.nlm.nih.gov/pubmed/25712094">PubMed Abstract </a> | <a target=xrefwindow id=d18937e938 href="https://doi.org/10.1093/nar/gkv143">Publisher Full Text </a> | <a target=xrefwindow id=d18937e942 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4357732">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733135285"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e951 class=n-a></a>Zanardi TA, Kim TW, Shen L, <i> et al.</i>: Chronic Toxicity Assessment of 2'-O-Methoxyethyl Antisense Oligonucleotides in Mice. <i>Nucleic Acid Ther.</i> 2018; <b>28</b>(4): 233–41. <a target=xrefwindow id=d18937e962 href="http://www.ncbi.nlm.nih.gov/pubmed/29708844">PubMed Abstract </a> | <a target=xrefwindow id=d18937e965 href="https://doi.org/10.1089/nat.2017.0706">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733135285">F1000 Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d18937e978 class=n-a></a>Stein CA: Eteplirsen Approved for Duchenne Muscular Dystrophy: The FDA Faces a Difficult Choice. <i>Mol Ther.</i> 2016; <b>24</b>(11): 1884–5. <a target=xrefwindow id=d18937e986 href="http://www.ncbi.nlm.nih.gov/pubmed/27916994">PubMed Abstract </a> | <a target=xrefwindow id=d18937e989 href="https://doi.org/10.1038/mt.2016.188">Publisher Full Text </a> | <a target=xrefwindow id=d18937e992 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5154484">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d18937e1001 class=n-a></a>Li D, Mastaglia FL, Fletcher S, <i> et al.</i>: Precision Medicine through Antisense Oligonucleotide-Mediated Exon Skipping. <i>Trends Pharmacol Sci.</i> 2018; <b>39</b>(11): 982–94. <a target=xrefwindow id=d18937e1012 href="http://www.ncbi.nlm.nih.gov/pubmed/30282590">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1015 href="https://doi.org/10.1016/j.tips.2018.09.001">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732298839"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e1025 class=n-a></a>Shen X, Corey DR: Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. <i>Nucleic Acids Res.</i> 2018; <b>46</b>(4): 1584–600. <a target=xrefwindow id=d18937e1033 href="http://www.ncbi.nlm.nih.gov/pubmed/29240946">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1036 href="https://doi.org/10.1093/nar/gkx1239">Publisher Full Text </a> | <a target=xrefwindow id=d18937e1039 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5829639">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732298839">F1000 Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d18937e1052 class=n-a></a>Dominski Z, Kole R: Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. <i>Proc Natl Acad Sci U S A.</i> 1993; <b>90</b>(18): 8673–7. <a target=xrefwindow id=d18937e1060 href="http://www.ncbi.nlm.nih.gov/pubmed/8378346">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1063 href="https://doi.org/10.1073/pnas.90.18.8673">Publisher Full Text </a> | <a target=xrefwindow id=d18937e1066 href="http://www.ncbi.nlm.nih.gov/pmc/articles/47420">Free Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734999550"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e1075 class=n-a></a>Yin W, Rogge M: Targeting RNA: A Transformative Therapeutic Strategy. <i>Clin Transl Sci.</i> 2019; <b>12</b>(2): 98–112. <a target=xrefwindow id=d18937e1083 href="http://www.ncbi.nlm.nih.gov/pubmed/30706991">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1086 href="https://doi.org/10.1111/cts.12624">Publisher Full Text </a> | <a target=xrefwindow id=d18937e1089 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6440575">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734999550">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d18937e1102 class=n-a></a>Havens MA, Hastings ML: Splice-switching antisense oligonucleotides as therapeutic drugs. <i>Nucleic Acids Res.</i> 2016; <b>44</b>(14): 6549–63. <a target=xrefwindow id=d18937e1110 href="http://www.ncbi.nlm.nih.gov/pubmed/27288447">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1113 href="https://doi.org/10.1093/nar/gkw533">Publisher Full Text </a> | <a target=xrefwindow id=d18937e1116 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5001604">Free Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725940978"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e1125 class=n-a></a>Mendell JR, Goemans N, Lowes LP, <i> et al.</i>: Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. <i>Ann Neurol.</i> 2016; <b>79</b>(2): 257–71. <a target=xrefwindow id=d18937e1136 href="http://www.ncbi.nlm.nih.gov/pubmed/26573217">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1139 href="https://doi.org/10.1002/ana.24555">Publisher Full Text </a> | <a target=xrefwindow id=d18937e1143 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5064753">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725940978">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d18937e1156 class=n-a></a>Paton DM: Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy. <i>Drugs Today (Barc).</i> 2017; <b>53</b>(6): 327–37. <a target=xrefwindow id=d18937e1164 href="http://www.ncbi.nlm.nih.gov/pubmed/28799578">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1167 href="https://doi.org/10.1358/dot.2017.53.6.2652413">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d18937e1177 class=n-a></a>Singh NK, Singh NN, Androphy EJ, <i> et al.</i>: Splicing of a critical exon of human <i>Survival Motor Neuron</i> is regulated by a unique silencer element located in the last intron. <i>Mol Cell Biol.</i> 2006; <b>26</b>(4): 1333–46. <a target=xrefwindow id=d18937e1191 href="http://www.ncbi.nlm.nih.gov/pubmed/16449646">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1195 href="https://doi.org/10.1128/MCB.26.4.1333-1346.2006">Publisher Full Text </a> | <a target=xrefwindow id=d18937e1198 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1367187">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d18937e1207 class=n-a></a>Wilton SD, Veedu RN, Fletcher S: The emperor's new dystrophin: finding sense in the noise. <i>Trends Mol Med.</i> 2015; <b>21</b>(7): 417–26. <a target=xrefwindow id=d18937e1215 href="http://www.ncbi.nlm.nih.gov/pubmed/26051381">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1218 href="https://doi.org/10.1016/j.molmed.2015.04.006">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d18937e1227 class=n-a></a>Goemans NM, Tulinius M, van den Hauwe M, <i> et al.</i>: Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study. <i>PLoS One.</i> 2016; <b>11</b>(9): e0161955. <a target=xrefwindow id=d18937e1238 href="http://www.ncbi.nlm.nih.gov/pubmed/27588424">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1241 href="https://doi.org/10.1371/journal.pone.0161955">Publisher Full Text </a> | <a target=xrefwindow id=d18937e1245 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5010191">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734461146"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e1254 class=n-a></a>Hilhorst N, Spanoudi-Kitrimi I, Goemans N, <i> et al.</i>: Injection site reactions after long-term subcutaneous delivery of drisapersen: a retrospective study. <i>Eur J Pediatr.</i> 2019; <b>178</b>(2): 253–8. <a target=xrefwindow id=d18937e1265 href="http://www.ncbi.nlm.nih.gov/pubmed/30448867">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1268 href="https://doi.org/10.1007/s00431-018-3272-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734461146">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727480507"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e1281 class=n-a></a>Sardone V, Zhou H, Muntoni F, <i> et al.</i>: Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease. <i>Molecules.</i> 2017; <b>22</b>(4): pii: E563. <a target=xrefwindow id=d18937e1292 href="http://www.ncbi.nlm.nih.gov/pubmed/28379182">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1295 href="https://doi.org/10.3390/molecules22040563">Publisher Full Text </a> | <a target=xrefwindow id=d18937e1299 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6154734">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727480507">F1000 Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732501490"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e1312 class=n-a></a>Domingos J, Ricotti V, Martinez AE, <i> et al.</i>: Severe persistent injection site reactions after subcutaneous 2'-O-methyl phosphorothioate oligonucleotide therapy for Duchenne muscular dystrophy. <i>Neuromuscul Disord.</i> 2018; <b>28</b>(2): 176–7. <a target=xrefwindow id=d18937e1323 href="http://www.ncbi.nlm.nih.gov/pubmed/29305134">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1326 href="https://doi.org/10.1016/j.nmd.2017.11.015">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732501490">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d18937e1340 class=n-a></a>Kesselheim AS, Avorn J: Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy. <i>JAMA.</i> 2016; <b>316</b>(22): 2357–8. <a target=xrefwindow id=d18937e1348 href="http://www.ncbi.nlm.nih.gov/pubmed/27775756">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1351 href="https://doi.org/10.1001/jama.2016.16437">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d18937e1360 class=n-a></a>Kesselheim AS, Avorn J: FDA Approval of Eteplirsen for Muscular Dystrophy-Reply. <i>JAMA.</i> 2017; <b>317</b>(14): 1481–2. <a target=xrefwindow id=d18937e1368 href="http://www.ncbi.nlm.nih.gov/pubmed/28399248">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1371 href="https://doi.org/10.1001/jama.2017.2605">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d18937e1380 class=n-a></a>Nelson SF, Miceli MC: FDA Approval of Eteplirsen for Muscular Dystrophy. <i>JAMA.</i> 2017; <b>317</b>(14): 1480. <a target=xrefwindow id=d18937e1388 href="http://www.ncbi.nlm.nih.gov/pubmed/28399245">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1391 href="https://doi.org/10.1001/jama.2017.2601">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d18937e1400 class=n-a></a>Sackner-Bernstein J: FDA Approval of Eteplirsen for Muscular Dystrophy. <i>JAMA.</i> 2017; <b>317</b>(14): 1480–1. <a target=xrefwindow id=d18937e1408 href="http://www.ncbi.nlm.nih.gov/pubmed/28399244">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1411 href="https://doi.org/10.1001/jama.2017.2597">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732381646"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e1420 class=n-a></a>Kinane TB, Mayer OH, Duda PW, <i> et al.</i>: Long-Term Pulmonary Function in Duchenne Muscular Dystrophy: Comparison of Eteplirsen-Treated Patients to Natural History. <i>J Neuromuscul Dis.</i> 2018; <b>5</b>(1): 47–58. <a target=xrefwindow id=d18937e1431 href="http://www.ncbi.nlm.nih.gov/pubmed/29278896">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1434 href="https://doi.org/10.3233/JND-170272">Publisher Full Text </a> | <a target=xrefwindow id=d18937e1438 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5836407">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732381646">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733222528"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e1451 class=n-a></a>Charleston JS, Schnell FJ, Dworzak J, <i> et al.</i>: Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production. <i>Neurology.</i> 2018; <b>90</b>(24): e2146–e2154. <a target=xrefwindow id=d18937e1462 href="http://www.ncbi.nlm.nih.gov/pubmed/29752304">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1465 href="https://doi.org/10.1212/WNL.0000000000005680">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733222528">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/729274840"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e1479 class=n-a></a>Dalakas MC: Gene therapy for Duchenne muscular dystrophy: balancing good science, marginal efficacy, high emotions and excessive cost. <i>Ther Adv Neurol Disord.</i> 2017; <b>10</b>(8): 293–6. <a target=xrefwindow id=d18937e1487 href="http://www.ncbi.nlm.nih.gov/pubmed/28781610">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1490 href="https://doi.org/10.1177/1756285617717155">Publisher Full Text </a> | <a target=xrefwindow id=d18937e1493 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5518962">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/729274840">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d18937e1506 class=n-a></a>Sugarman EA, Nagan N, Zhu H, <i> et al.</i>: Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of &gt;72,400 specimens. <i>Eur J Hum Genet.</i> 2012; <b>20</b>(1): 27–32. <a target=xrefwindow id=d18937e1517 href="http://www.ncbi.nlm.nih.gov/pubmed/21811307">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1520 href="https://doi.org/10.1038/ejhg.2011.134">Publisher Full Text </a> | <a target=xrefwindow id=d18937e1524 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3234503">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732062321"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e1533 class=n-a></a>Finkel RS, Mercuri E, Darras BT, <i> et al.</i>: Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. <i>N Engl J Med.</i> 2017; <b>377</b>(18): 1723–32. <a target=xrefwindow id=d18937e1544 href="http://www.ncbi.nlm.nih.gov/pubmed/29091570">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1547 href="https://doi.org/10.1056/NEJMoa1702752">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732062321">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d18937e1560 class=n-a></a>CADTH Canadian Drug Expert Committee Recommendation: Nusinersen (Spinraza — Biogen Canada Inc.): Indication: Treatment of 5q Spinal Muscular Atrophy [Internet]. Ottawa (ON) 2017. <a target=xrefwindow id=d18937e1562 href="http://www.ncbi.nlm.nih.gov/pubmed/30457792">PubMed Abstract </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734029076"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e1571 class=n-a></a>Gidaro T, Servais L: Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps. <i>Dev Med Child Neurol.</i> 2019; <b>61</b>(1): 19–24. <a target=xrefwindow id=d18937e1579 href="http://www.ncbi.nlm.nih.gov/pubmed/30221755">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1582 href="https://doi.org/10.1111/dmcn.14027">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734029076">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d18937e1595 class=n-a></a>Watanabe N, Nagata T, Satou Y, <i> et al.</i>: NS-065/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy. <i>Mol Ther Nucleic Acids.</i> 2018; <b>13</b>: 442–9. <a target=xrefwindow id=d18937e1606 href="http://www.ncbi.nlm.nih.gov/pubmed/30388618">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1609 href="https://doi.org/10.1016/j.omtn.2018.09.017">Publisher Full Text </a> | <a target=xrefwindow id=d18937e1613 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6202794">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733068497"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e1623 class=n-a></a>Komaki H, Nagata T, Saito T, <i> et al.</i>: Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy. <i>Sci Transl Med.</i> 2018; <b>10</b>(437): pii: eaan0713. <a target=xrefwindow id=d18937e1634 href="http://www.ncbi.nlm.nih.gov/pubmed/29669851">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1637 href="https://doi.org/10.1126/scitranslmed.aan0713">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733068497">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735754207"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e1650 class=n-a></a>Garanto A, van der Velde-Visser SD, Cremers FPM, <i> et al.</i>: Antisense Oligonucleotide-Based Splice Correction of a Deep-Intronic Mutation in <i>CHM</i> Underlying Choroideremia. <i>Adv Exp Med Biol.</i> 2018; <b>1074</b>: 83–9. <a target=xrefwindow id=d18937e1664 href="http://www.ncbi.nlm.nih.gov/pubmed/29721931">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1668 href="https://doi.org/10.1007/978-3-319-75402-4_11">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735754207">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d18937e1681 class=n-a></a>Garanto A, Chung DC, Duijkers L, <i> et al.</i>: <i>In vitro</i> and <i>in vivo</i> rescue of aberrant splicing in <i>CEP290</i>-associated LCA by antisense oligonucleotide delivery. <i>Hum Mol Genet.</i> 2016; <b>25</b>(12): 2552–63. <a target=xrefwindow id=d18937e1702 href="http://www.ncbi.nlm.nih.gov/pubmed/27106101">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1705 href="https://doi.org/10.1093/hmg/ddw118">Publisher Full Text </a> | <a target=xrefwindow id=d18937e1708 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6086559">Free Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d18937e1717 class=n-a></a>Slijkerman RW, Vaché C, Dona M, <i> et al.</i>: Antisense Oligonucleotide-based Splice Correction for <i>USH2A</i>-associated Retinal Degeneration Caused by a Frequent Deep-intronic Mutation. <i>Mol Ther Nucleic Acids.</i> 2016; <b>5</b>(10): e381. <a target=xrefwindow id=d18937e1731 href="http://www.ncbi.nlm.nih.gov/pubmed/27802265">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1735 href="https://doi.org/10.1038/mtna.2016.89">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727724331"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e1744 class=n-a></a>van der Wal E, Bergsma AJ, Pijnenburg JM, <i> et al.</i>: Antisense Oligonucleotides Promote Exon Inclusion and Correct the Common c.-32-13T&gt;G <i>GAA</i> Splicing Variant in Pompe Disease. <i>Mol Ther Nucleic Acids.</i> 2017; <b>7</b>: 90–100. <a target=xrefwindow id=d18937e1758 href="http://www.ncbi.nlm.nih.gov/pubmed/28624228">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1762 href="https://doi.org/10.1016/j.omtn.2017.03.001">Publisher Full Text </a> | <a target=xrefwindow id=d18937e1765 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5415969">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727724331">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731217459"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e1778 class=n-a></a>Toonen LJA, Rigo F, van Attikum H, <i> et al.</i>: Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice. <i>Mol Ther Nucleic Acids.</i> 2017; <b>8</b>: 232–42. <a target=xrefwindow id=d18937e1789 href="http://www.ncbi.nlm.nih.gov/pubmed/28918024">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1792 href="https://doi.org/10.1016/j.omtn.2017.06.019">Publisher Full Text </a> | <a target=xrefwindow id=d18937e1796 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5504086">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731217459">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d18937e1810 class=n-a></a>Toonen LJ, Schmidt I, Luijsterburg MS, <i> et al.</i>: Antisense oligonucleotide-mediated exon skipping as a strategy to reduce proteolytic cleavage of ataxin-3. <i>Sci Rep.</i> 2016; <b>6</b>: 35200. <a target=xrefwindow id=d18937e1821 href="http://www.ncbi.nlm.nih.gov/pubmed/27731380">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1824 href="https://doi.org/10.1038/srep35200">Publisher Full Text </a> | <a target=xrefwindow id=d18937e1828 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5059676">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d18937e1837 class=n-a></a>Li Z, Li Q, Han L, <i> et al.</i>: Pro-apoptotic effects of splice-switching oligonucleotides targeting Bcl-x pre-mRNA in human glioma cell lines. <i>Oncol Rep.</i> 2016; <b>35</b>(2): 1013–9. <a target=xrefwindow id=d18937e1848 href="http://www.ncbi.nlm.nih.gov/pubmed/26718027">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1851 href="https://doi.org/10.3892/or.2015.4465">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d18937e1860 class=n-a></a>Wu L, Mao C, Ming X: Modulation of Bcl-x Alternative Splicing Induces Apoptosis of Human Hepatic Stellate Cells. <i>Biomed Res Int.</i> 2016; <b>2016</b>: 7478650. <a target=xrefwindow id=d18937e1868 href="http://www.ncbi.nlm.nih.gov/pubmed/27579319">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1871 href="https://doi.org/10.1155/2016/7478650">Publisher Full Text </a> | <a target=xrefwindow id=d18937e1874 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4992517">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d18937e1883 class=n-a></a>McGlinchey JC, Tummala H, Lester DH: Correction of the Pathogenic Alternative Splicing, Caused by the Common <i>GNB3</i> c.825C&gt;T Allele, Using a Novel, Antisense Morpholino. <i>Nucleic Acid Ther.</i> 2016; <b>26</b>(4): 257–65. <a target=xrefwindow id=d18937e1894 href="http://www.ncbi.nlm.nih.gov/pubmed/27028457">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1897 href="https://doi.org/10.1089/nat.2015.0571">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d18937e1906 class=n-a></a>Luo YB, Mastaglia FL, Wilton SD: Normal and aberrant splicing of <i>LMNA</i>. <i>J Med Genet.</i> 2014; <b>51</b>(4): 215–23. <a target=xrefwindow id=d18937e1917 href="http://www.ncbi.nlm.nih.gov/pubmed/24459210">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1920 href="https://doi.org/10.1136/jmedgenet-2013-102119">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d18937e1929 class=n-a></a>Lee JM, Nobumori C, Tu Y, <i> et al.</i>: Modulation of <i>LMNA</i> splicing as a strategy to treat prelamin A diseases. <i>J Clin Invest.</i> 2016; <b>126</b>(4): 1592–602. <a target=xrefwindow id=d18937e1943 href="http://www.ncbi.nlm.nih.gov/pubmed/26999604">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1947 href="https://doi.org/10.1172/JCI85908">Publisher Full Text </a> | <a target=xrefwindow id=d18937e1950 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4811112">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d18937e1960 class=n-a></a>Fletcher S, Honeyman K, Fall AM, <i> et al.</i>: Dystrophin expression in the <i>mdx</i> mouse after localised and systemic administration of a morpholino antisense oligonucleotide. <i>J Gene Med.</i> 2006; <b>8</b>(2): 207–16. <a target=xrefwindow id=d18937e1974 href="http://www.ncbi.nlm.nih.gov/pubmed/16285002">PubMed Abstract </a> | <a target=xrefwindow id=d18937e1978 href="https://doi.org/10.1002/jgm.838">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d18937e1987 class=n-a></a>Amantana A, Moulton HM, Cate ML, <i> et al.</i>: Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. <i>Bioconjug Chem.</i> 2007; <b>18</b>(4): 1325–31. <a target=xrefwindow id=d18937e1998 href="http://www.ncbi.nlm.nih.gov/pubmed/17583927">PubMed Abstract </a> | <a target=xrefwindow id=d18937e2001 href="https://doi.org/10.1021/bc070060v">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d18937e2010 class=n-a></a>Hoffmann K, Milech N, Juraja SM, <i> et al.</i>: A platform for discovery of functional cell-penetrating peptides for efficient multi-cargo intracellular delivery. <i>Sci Rep.</i> 2018; <b>8</b>(1): 12538. <a target=xrefwindow id=d18937e2021 href="http://www.ncbi.nlm.nih.gov/pubmed/30135446">PubMed Abstract </a> | <a target=xrefwindow id=d18937e2024 href="https://doi.org/10.1038/s41598-018-30790-2">Publisher Full Text </a> | <a target=xrefwindow id=d18937e2028 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6105642">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733397899"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e2037 class=n-a></a>Gao X, Ran N, Dong X, <i> et al.</i>: Anchor peptide captures, targets, and loads exosomes of diverse origins for diagnostics and therapy. <i>Sci Transl Med.</i> 2018; <b>10</b>(444): pii: eaat0195. <a target=xrefwindow id=d18937e2048 href="http://www.ncbi.nlm.nih.gov/pubmed/29875202">PubMed Abstract </a> | <a target=xrefwindow id=d18937e2051 href="https://doi.org/10.1126/scitranslmed.aat0195">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733397899">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735095532"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e2064 class=n-a></a>Miyatake S, Mizobe Y, Tsoumpra MK, <i> et al.</i>: Scavenger Receptor Class A1 Mediates Uptake of Morpholino Antisense Oligonucleotide into Dystrophic Skeletal Muscle. <i>Mol Ther Nucleic Acids.</i> 2019; <b>14</b>: 520–35. <a target=xrefwindow id=d18937e2075 href="http://www.ncbi.nlm.nih.gov/pubmed/30763772">PubMed Abstract </a> | <a target=xrefwindow id=d18937e2078 href="https://doi.org/10.1016/j.omtn.2019.01.008">Publisher Full Text </a> | <a target=xrefwindow id=d18937e2082 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6374502">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735095532">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734600071"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e2095 class=n-a></a>Hori SI, Mitsuoka Y, Kugimiya A: RNA Reduction and Hepatotoxic Potential Caused by Non-Gapmer Antisense Oligonucleotides. <i>Nucleic Acid Ther.</i> 2019; <b>29</b>(1): 44–50. <a target=xrefwindow id=d18937e2103 href="http://www.ncbi.nlm.nih.gov/pubmed/30508397">PubMed Abstract </a> | <a target=xrefwindow id=d18937e2106 href="https://doi.org/10.1089/nat.2018.0741">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734600071">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d18937e2120 class=n-a></a>Hvam ML, Cai Y, Dagnæs-Hansen F, <i> et al.</i>: Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation. <i>Mol Ther.</i> 2017; <b>25</b>(7): 1710–7. <a target=xrefwindow id=d18937e2131 href="http://www.ncbi.nlm.nih.gov/pubmed/28641935">PubMed Abstract </a> | <a target=xrefwindow id=d18937e2134 href="https://doi.org/10.1016/j.ymthe.2017.05.009">Publisher Full Text </a> | <a target=xrefwindow id=d18937e2138 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5498835">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d18937e2147 class=n-a></a>Summerton JE: Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity. <i>Curr Top Med Chem.</i> 2007; <b>7</b>(7): 651–60. <a target=xrefwindow id=d18937e2155 href="http://www.ncbi.nlm.nih.gov/pubmed/17430206">PubMed Abstract </a> | <a target=xrefwindow id=d18937e2158 href="https://doi.org/10.2174/156802607780487740">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732900592"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e2167 class=n-a></a>Toonen LJA, Casaca-Carreira J, Pellisé-Tintoré M, <i> et al.</i>: Intracerebroventricular Administration of a 2'-O-Methyl Phosphorothioate Antisense Oligonucleotide Results in Activation of the Innate Immune System in Mouse Brain. <i>Nucleic Acid Ther.</i> 2018; <b>28</b>(2): 63–73. <a target=xrefwindow id=d18937e2178 href="http://www.ncbi.nlm.nih.gov/pubmed/29565739">PubMed Abstract </a> | <a target=xrefwindow id=d18937e2181 href="https://doi.org/10.1089/nat.2017.0705">Publisher Full Text </a> | <a target=xrefwindow id=d18937e2185 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5899290">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732900592">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730151370"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e2198 class=n-a></a>van Meer L, Moerland M, Gallagher J, <i> et al.</i>: Injection site reactions after subcutaneous oligonucleotide therapy. <i>Br J Clin Pharmacol.</i> 2016; <b>82</b>(2): 340–51. <a target=xrefwindow id=d18937e2209 href="http://www.ncbi.nlm.nih.gov/pubmed/27061947">PubMed Abstract </a> | <a target=xrefwindow id=d18937e2212 href="https://doi.org/10.1111/bcp.12961">Publisher Full Text </a> | <a target=xrefwindow id=d18937e2216 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4972150">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730151370">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d18937e2229 class=n-a></a>Dürig J, Dührsen U, Klein-Hitpass L, <i> et al.</i>: The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia. <i>Leukemia.</i> 2011; <b>25</b>(4): 638–47. <a target=xrefwindow id=d18937e2240 href="http://www.ncbi.nlm.nih.gov/pubmed/21358717">PubMed Abstract </a> | <a target=xrefwindow id=d18937e2243 href="https://doi.org/10.1038/leu.2010.322">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d18937e2252 class=n-a></a>Flierl U, Nero TL, Lim B, <i> et al.</i>: Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators. <i>J Exp Med.</i> 2015; <b>212</b>(2): 129–37. <a target=xrefwindow id=d18937e2263 href="http://www.ncbi.nlm.nih.gov/pubmed/25646267">PubMed Abstract </a> | <a target=xrefwindow id=d18937e2266 href="https://doi.org/10.1084/jem.20140391">Publisher Full Text </a> | <a target=xrefwindow id=d18937e2270 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4322051">Free Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732516564"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e2280 class=n-a></a>Dieckmann A, Hagedorn PH, Burki Y, <i> et al.</i>: A Sensitive <i>In Vitro</i> Approach to Assess the Hybridization-Dependent Toxic Potential of High Affinity Gapmer Oligonucleotides. <i>Mol Ther Nucleic Acids.</i> 2018; <b>10</b>: 45–54. <a target=xrefwindow id=d18937e2294 href="http://www.ncbi.nlm.nih.gov/pubmed/29499955">PubMed Abstract </a> | <a target=xrefwindow id=d18937e2298 href="https://doi.org/10.1016/j.omtn.2017.11.004">Publisher Full Text </a> | <a target=xrefwindow id=d18937e2301 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5725219">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732516564">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d18937e2314 class=n-a></a>Thomas GS, Cromwell WC, Ali S, <i> et al.</i>: Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. <i>J Am Coll Cardiol.</i> 2013; <b>62</b>(23): 2178–84. <a target=xrefwindow id=d18937e2325 href="http://www.ncbi.nlm.nih.gov/pubmed/24013058">PubMed Abstract </a> | <a target=xrefwindow id=d18937e2328 href="https://doi.org/10.1016/j.jacc.2013.07.081">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d18937e2337 class=n-a></a>Waldmann E, Vogt A, Crispin A, <i> et al.</i>: Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study). <i>Atherosclerosis.</i> 2017; <b>259</b>: 20–5. <a target=xrefwindow id=d18937e2348 href="http://www.ncbi.nlm.nih.gov/pubmed/28279833">PubMed Abstract </a> | <a target=xrefwindow id=d18937e2351 href="https://doi.org/10.1016/j.atherosclerosis.2017.02.019">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d18937e2360 class=n-a></a>Shen W, Liang XH, Crooke ST: Phosphorothioate oligonucleotides can displace <i>NEAT1</i> RNA and form nuclear paraspeckle-like structures. <i>Nucleic Acids Res.</i> 2014; <b>42</b>(13): 8648–62. <a target=xrefwindow id=d18937e2371 href="http://www.ncbi.nlm.nih.gov/pubmed/25013176">PubMed Abstract </a> | <a target=xrefwindow id=d18937e2374 href="https://doi.org/10.1093/nar/gku579">Publisher Full Text </a> | <a target=xrefwindow id=d18937e2378 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4117792">Free Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731792365"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e2387 class=n-a></a>Bailey JK, Shen W, Liang XH, <i> et al.</i>: Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides. <i>Nucleic Acids Res.</i> 2017; <b>45</b>(18): 10649–71. <a target=xrefwindow id=d18937e2398 href="http://www.ncbi.nlm.nih.gov/pubmed/28977508">PubMed Abstract </a> | <a target=xrefwindow id=d18937e2401 href="https://doi.org/10.1093/nar/gkx709">Publisher Full Text </a> | <a target=xrefwindow id=d18937e2405 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5737868">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731792365">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d18937e2418 class=n-a></a>Shen W, Liang XH, Sun H, <i> et al.</i>: 2'-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF. <i>Nucleic Acids Res.</i> 2015; <b>43</b>(9): 4569–78. <a target=xrefwindow id=d18937e2429 href="http://www.ncbi.nlm.nih.gov/pubmed/25855809">PubMed Abstract </a> | <a target=xrefwindow id=d18937e2432 href="https://doi.org/10.1093/nar/gkv298">Publisher Full Text </a> | <a target=xrefwindow id=d18937e2436 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4482069">Free Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d18937e2446 class=n-a></a>Flynn LL, Li R, Aung-Htut MT, <i> et al.</i>: Interaction of modified oligonucleotides with nuclear proteins, formation of novel nuclear structures and sequence-independent effects on RNA processing. <i>bioRxiv.</i> 2019. <a target=xrefwindow id=d18937e2454 href="https://doi.org/10.1101/446773">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d18937e2463 class=n-a></a>Dias N, Stein CA: Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides. <i>Eur J Pharm Biopharm.</i> 2002; <b>54</b>(3): 263–9. <a target=xrefwindow id=d18937e2471 href="http://www.ncbi.nlm.nih.gov/pubmed/12445555">PubMed Abstract </a> | <a target=xrefwindow id=d18937e2474 href="https://doi.org/10.1016/S0939-6411(02)00060-7">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d18937e2483 class=n-a></a>Migawa MT, Shen W, Wan WB, <i> et al.</i>: Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins. <i>Nucleic Acids Res.</i> 2019; pii: gkz247. <a target=xrefwindow id=d18937e2491 href="http://www.ncbi.nlm.nih.gov/pubmed/31034558">PubMed Abstract </a> | <a target=xrefwindow id=d18937e2494 href="https://doi.org/10.1093/nar/gkz247">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735646194"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18937e2503 class=n-a></a>Shen W, De Hoyos CL, Migawa MT, <i> et al.</i>: Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. <i>Nat Biotechnol.</i> 2019. <a target=xrefwindow id=d18937e2511 href="http://www.ncbi.nlm.nih.gov/pubmed/31036929">PubMed Abstract </a> | <a target=xrefwindow id=d18937e2514 href="https://doi.org/10.1038/s41587-019-0106-2">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735646194">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d18937e2527 class=n-a></a>Reshat R, Priestley CC, Gooderham NJ: Mutagenesis by an antisense oligonucleotide and its degradation product. <i>Toxicol Sci.</i> 2012; <b>130</b>(2): 319–27. <a target=xrefwindow id=d18937e2535 href="http://www.ncbi.nlm.nih.gov/pubmed/22872057">PubMed Abstract </a> | <a target=xrefwindow id=d18937e2538 href="https://doi.org/10.1093/toxsci/kfs247">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 22 May 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-710.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-710.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Murdoch University, Murdoch, WA, 6150, Australia<br/> <sup>2</sup> The University of Western Australia, Nedlands, WA, 6009, Australia<br/> <sup>3</sup> Perron Institute, Nedlands, WA, 6009, Australia<br/> <p> <div class=margin-bottom> Ianthe Pitout <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Loren L. Flynn <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Steve D. Wilton <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Sue Fletcher <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-710/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 22 May 2019, 8:710 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.18466.1">https://doi.org/10.12688/f1000research.18466.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2019 Pitout I <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=20203 data-id=18466 data-downloads="" data-views="" data-scholar="10.12688/f1000research.18466.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-710/v1/pdf?article_uuid=78a31033-6e85-4dad-a79f-5178f8be5643" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.18466.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Pitout I, Flynn LL, Wilton SD and Fletcher S. Antisense-mediated splice intervention to treat human disease: the odyssey continues [version 1; peer review: 3 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):710 (<a href="https://doi.org/10.12688/f1000research.18466.1" target=_blank>https://doi.org/10.12688/f1000research.18466.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=18466 id=mobile-track-article-signin-18466 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/18466?target=/articles/8-710.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=20203 /> <input name=articleId type=hidden value=18466 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Cy Stein</strong>, Department of Medical Oncology, City of Hope, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Satoshi Obika</strong>, Graduate School of Pharmaceutical Sciences, Osaka University, Japan </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Michelle Hastings</strong>, Department of Cell Biology and Anatomy, Center for Genetic Diseases, Chicago Medical School and School of Graduate and Postdoctoral Studies, Rosalind Franklin University of Medicine and Science, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 22 May 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-710.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-710.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=51010-48520></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=51011-48521></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=51012-48519></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-710/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>22 May 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Cy Stein</strong>, Department of Medical Oncology, City of Hope, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Satoshi Obika</strong>, Graduate School of Pharmaceutical Sciences, Osaka University, Japan </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Michelle Hastings</strong>, Department of Cell Biology and Anatomy, Center for Genetic Diseases, Chicago Medical School and School of Graduate and Postdoctoral Studies, Rosalind Franklin University of Medicine and Science, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-710.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-710/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Antisense-mediated splice intervention to...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-710/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-710/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-710/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Pitout I et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-710/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-710",
            templates : {
                twitter : "Antisense-mediated splice intervention to treat human disease:.... Pitout I et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-710/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Antisense-mediated splice intervention to treat human disease: the odyssey continues", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Antisense-mediated splice intervention to treat human disease: the odyssey continues", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/18466/20203")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "20203");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "48519": 1,
                           "48520": 0,
                           "48521": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "fde0de0c-13f5-4e76-8f1b-0b93445e5120";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-710.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-710.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-710.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-710.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-710.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>